Interleukin Genetics Enters into New Clinical Research Collaboration wi...(innovative research in exercise performa...)

Date:2/28/2008

innovative research in exercise performance and skin health," said Lewis H. Bender, Chief Executive Officer of Interleukin Genetics. "The areas in which we are collaborating with Alticor represent attractive, important and large markets. Alticor's continued investment and commitment is an important endorsement in the development of risk assessment tests and personalized wellness products using our proprietary methods and intellectual property."

"Interleukin Genetics has an experienced research staff and the capabilities to assist in our development of novel personalized health and wellness products," said Robin Dykhouse, Vice President, Research at Access Business Group. "We have been pleased with our past collaborations with Interleukin Genetics and look forward to continuing to work with their team."

Previous research agreements between Interleukin Genetics and Alticor led to the commercial launch in March 2006 of three products--a proprietary genetic test for risk of early heart disease, a novel and proprietary nutritional supplement beneficial for those who test positive for that genetic risk factor, and a general nutrition test panel.

About Interleukin Genetics

Interleukin Genetics, Inc. (Amex: ILI) is a genetics-focused personalized health company that develops preventive consumer products and genetic tests for sale to the emerging personalized health market. Focused on the future of health and medicine, Interleukin uses its leading genetics research and scientific capabilities to develop and test innovative preventive and therapeutic products. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. The Company
'/>"/>

SOURCE Interleukin Genetics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Interleukin Genetics Announces Conversion of $2.04 Million of Debt Into Common Stock
2. Interleukin Genetics, Inc. Reports Third Quarter 2007 Financial Results
3. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
4. Interleukin Genetics Announces Management and Board Appointments
5. CellCyte Genetics Corp. Continues to Move Its Technology Forward in Light of Plaintiff Law Firm Press Releases
6. deCODE genetics to Webcast Presentation at BIO CEO and Investor Conference
7. Smart Genetics Announces Plans to Launch a New Alzheimers Risk Assessment Service
8. Finkelstein Thompson LLP Announces Filing of Securities Fraud Class Action Against CellCyte Genetics Corporation
9. Hagens Berman Sobol Shapiro: Lawsuit Filed Against CellCyte Genetics Corporation
10. CellCyte Genetics Corp. Responds to Plaintiff Law Firm Press Releases
11. deCODE genetics to Webcast Presentation at JPMorgan Annual Healthcare Conference